Ibuprofen; phenylephrine hydrochloride - Generic Drug Details

What are the generic sources for ibuprofen; phenylephrine hydrochloride and what is the scope of freedom to operate?

Ibuprofen; phenylephrine hydrochloride is the generic ingredient in two branded drugs marketed by Haleon Us Holdings and Perrigo R And D, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Six suppliers are listed for this compound.

Summary for ibuprofen; phenylephrine hydrochloride

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	6
Clinical Trials:	4
DailyMed Link:	ibuprofen; phenylephrine hydrochloride at DailyMed

Recent Clinical Trials for ibuprofen; phenylephrine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of North Carolina, Chapel Hill	PHASE4
Ache Laboratorios Farmaceuticos S.A.	Phase 3
Pfizer	Phase 3

See all ibuprofen; phenylephrine hydrochloride clinical trials

Pharmacology for ibuprofen; phenylephrine hydrochloride

Drug Class	Nonsteroidal Anti-inflammatory Drug alpha-1 Adrenergic Agonist
Mechanism of Action	Adrenergic alpha1-Agonists Cyclooxygenase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ibuprofen; phenylephrine hydrochloride

C01CA	Adrenergic and dopaminergic agents
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01	CARDIAC THERAPY
C	Cardiovascular system

C01EB	Other cardiac preparations
C01E	OTHER CARDIAC PREPARATIONS
C01	CARDIAC THERAPY
C	Cardiovascular system

C05AX	Other agents for treatment of hemorrhoids and anal fissures for topical use
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05	VASOPROTECTIVES
C	Cardiovascular system

G02CC	Antiinflammatory products for vaginal administration
G02C	OTHER GYNECOLOGICALS
G02	OTHER GYNECOLOGICALS
G	Genito-urinary system and sex hormones

M01AE	Propionic acid derivatives
M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M	Musculo-skeletal system

M02AA	Antiinflammatory preparations, non-steroids for topical use
M02A	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M02	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M	Musculo-skeletal system

R01AA	Sympathomimetics, plain
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R01AB	Sympathomimetics, combinations excl. corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R01BA	Sympathomimetics
R01B	NASAL DECONGESTANTS FOR SYSTEMIC USE
R01	NASAL PREPARATIONS
R	Respiratory system

R02AX	Other throat preparations
R02A	THROAT PREPARATIONS
R02	THROAT PREPARATIONS
R	Respiratory system

S01FB	Sympathomimetics excl. antiglaucoma preparations
S01F	MYDRIATICS AND CYCLOPLEGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01GA	Sympathomimetics used as decongestants
S01G	DECONGESTANTS AND ANTIALLERGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for ibuprofen; phenylephrine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Haleon Us Holdings	ADVIL CONGESTION RELIEF	ibuprofen; phenylephrine hydrochloride	TABLET;ORAL	022565-001	May 27, 2010		OTC	Yes	Yes
Perrigo R And D	IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE	ibuprofen; phenylephrine hydrochloride	TABLET;ORAL	203200-001	Jul 3, 2014		OTC	No	No

Expired US Patents for ibuprofen; phenylephrine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Haleon Us Holdings	ADVIL CONGESTION RELIEF	ibuprofen; phenylephrine hydrochloride	TABLET;ORAL	022565-001	May 27, 2010

Ibuprofen; phenylephrine hydrochloride Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Dynamics for Ibuprofen and Phenylephrine Hydrochloride?

Global demand for both ibuprofen and phenylephrine hydrochloride is driven by several factors, including demographic trends, disease prevalence, and healthcare infrastructure.

Ibuprofen Market

The ibuprofen market benefits from its widespread use in pain relief, anti-inflammatory treatment, and fever reduction. It is classified as an over-the-counter (OTC) drug in many countries, which expands its consumer base.

Key Market Drivers

• Increasing prevalence of chronic pain, arthritis, and fever-related illnesses, especially in aging populations.
• Growing OTC drug sales, supported by regulatory relaxations and patent expirations.
• Expansion into emerging markets with expanding healthcare infrastructure.

Market Size and Projections

• The global ibuprofen market was valued at approximately USD 4.6 billion in 2022.
• Compound annual growth rate (CAGR) is projected at 4.2% from 2023 to 2030.
• Key segments include low-dose formulations (200 mg) used in OTC products and higher-dose products for prescription use.

Phenylephrine Hydrochloride Market

Phenylephrine hydrochloride is used as a decongestant in OTC cold and allergy medications, as well as in certain injectable forms for vascular conditions. Its demand is largely derived from OTC formulations, which have a significant market share in respiratory relief.

Key Market Drivers

• Continued consumer preference for OTC cold remedies, especially in North America and Europe.
• Regulatory considerations, as some markets reevaluate phenylephrine’s efficacy in oral formulations, potentially impacting sales.
• Expansion in combination products for multi-symptom relief.

Market Size and Projections

• The phenylephrine market was valued at approximately USD 250 million in 2022.
• Annual growth rate estimated at 3.5%, with a potential slowdown due to regulatory critiques.
• The decongestant segment remains dominant, with a shift towards nasal sprays and sublingual delivery systems.

Competitive Landscape

For Ibuprofen

• Major players include Johnson & Johnson, Pfizer, and Reckitt Benckiser.
• Market strategies focus on formulation innovations, extended-release options, and branding.

For Phenylephrine Hydrochloride

• Dominated by large pharmaceutical firms like Bayer and GlaxoSmithKline.
• Market entries often involve combination OTC formulations with other active ingredients.

Regulatory Environment

• Efficacy, safety, and marketing restrictions significantly influence market growth.
• Both drugs face scrutiny: ibuprofen for gastrointestinal side effects, phenylephrine for questionable efficacy in oral formulations (FDA review ongoing).

What Are the Financial Trajectories for These Drugs?

Revenue Trends

Drug	2022 Market Value	Estimated CAGR (2023-2030)	Projected 2030 Market Value
Ibuprofen	USD 4.6 billion	4.2%	USD 6.5 billion
Phenylephrine	USD 250 million	3.5%	USD 340 million

Revenue by Region

• North America accounts for approximately 45% of the ibuprofen market and is the largest market globally.
• Europe contributes about 30%, with regulatory bodies like the EMA influencing product formulations.
• Asia-Pacific shows rapid growth, driven by expanding healthcare access and OTC sales.

Investment and R&D Considerations

• Ibuprofen’s mature market limits high-growth opportunities but fosters innovation in formulations and delivery methods.
• Phenylephrine’s market may see R&D efforts directed toward alternative decongestants due to efficacy debates, potentially impacting product pipelines.

Risk Factors

• Regulatory restrictions could limit sales, especially regarding efficacy disputes.
• Competition from alternative active ingredients (e.g., pseudoephedrine, phenylethylamine derivatives).
• Supply chain disruptions for raw materials, like acetic anhydride for ibuprofen synthesis, can impact production costs.

How Do These Drugs Fit in Broader Market Trends?

• Shift toward combination OTC drugs increases demand for both drugs within multi-ingredient formulations.
• Consumer preferences for natural and herbal alternatives may impact growth trajectories.
• Patent expirations on branded formulations promote generic competition, exerting downward pressure on prices.

What Are the Future Market Opportunities and Challenges?

Opportunities

• Development of formulation innovations, such as controlled-release and nasal spray delivery for phenylephrine.
• Expansion into emerging markets with higher economic growth and unmet medical needs.
• Strategic partnerships for distribution and co-marketing.

Challenges

• Evolving regulatory standards threaten efficacy claims, especially for phenylephrine.
• Potential legal liabilities related to safety concerns with long-term use of NSAIDs like ibuprofen.
• Market saturation in mature regions limits growth opportunities.

---

Key Takeaways

• The ibuprofen market is mature, with steady growth driven by OTC demand, but faces regulatory and competitive pressures.
• Phenylephrine hydrochloride's growth hinges on efficacy validation and regulatory acceptance, with an ongoing debate about its oral forms.
• Both markets are influenced by demographic shifts, technological innovation, and supply chain factors.
• Emerging markets represent significant growth opportunities through increased access and infrastructure development.
• R&D focus is shifting toward drug delivery improvements and combination therapies.

FAQs

1. Will regulatory restrictions on phenylephrine impact its market growth?
Yes. Regulatory scrutiny around efficacy could lead to bans or restrictions on oral formulations, reducing market size and prompting innovation or reformulation.

2. How do patent expirations affect the ibuprofen market?
They enable generics to enter, increasing competition, lowering prices, and expanding access, but limiting revenue growth for branded products.

3. What factors could derail growth projections for these drugs?
Regulatory crackdowns, safety concerns, competition from substitutes, and manufacturing disruptions.

4. Are natural or herbal alternatives affecting the demand for these drugs?
Yes, growing consumer interest in natural remedies could impact OTC sales, especially for ibuprofen, which faces competition from herbal anti-inflammatory options.

5. What upcoming regulatory changes should investors watch?
Efficacy reviews for phenylephrine by agencies like the FDA and EMA, as well as safety monitoring for NSAID use, could shape the market landscape.

---

Sources

[1] MarketWatch, “Ibuprofen Market Size, Share & Trends Analysis Report by Product, by Application,” 2023
[2] Grand View Research, “Phenylephrine Hydrochloride Market Size, Share & Trends,” 2023